EXHIBIT 16.1
March 8, 2018
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-6561
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated March 8, 2018 of IASO BioMed, Inc. and are in agreement with the statements contained therein as they relate to our firm.
Respectfully,
/s/ Moss Adams LLP